Cantargia: Breakthrough KRAS data reshapes PDAC landscape - Redeye

Revolution Medicines yesterday reported unprecedented phase III data for daraxonrasib in second-line PDAC, showing a near doubling of overall survival in patients with pancreatic cancer. The results are widely viewed as practice-changing and position KRAS inhibition as a new backbone in PDAC. We comment on the consequences for Cantargia.

Länk till analysen i sin helhet: https://www.redeye.se/research/1159603/cantargia-breakthrough-kras-data-reshapes-pdac-landscape?utm_source=finwire&utm_medium=RSS